Erythrocyte Lifespan Predicts Moderate to Severe Anemia in Advanced Gastric Cancer

Overview

This prospective study investigated erythrocyte lifespan (ELS) as a predictive biomarker for moderate to severe anemia in patients with advanced gastric cancer (AGC) undergoing anti-tumor treatments. Findings demonstrated that shorter baseline ELS correlates with lower hemoglobin levels post-treatment and can predict anemia development, highlighting its clinical utility.

Background

Gastric cancer is a leading cause of cancer-related mortality worldwide, with advanced gastric cancer (AGC) patients frequently developing anemia during chemotherapy, immunotherapy, or targeted therapy. Anemia adversely affects patient quality of life, treatment tolerance, and prognosis. Traditional anemia diagnosis relies on retrospective hemoglobin measurements, lacking predictive capability. Erythrocyte lifespan (ELS), measurable via a non-invasive CO breath test, reflects red blood cell turnover and may serve as an early predictor of anemia risk in this population.

Data Highlights

Key Findings

• Baseline ELS positively correlates with hemoglobin levels in AGC patients.
• Patients with ELS < 70 days have significantly lower hemoglobin compared to those with ELS ≥ 70 days.
• No significant difference in baseline ELS between patients with moderate-to-severe anemia and those with mild or no anemia at baseline.
• Post-treatment, the number of patients with moderate-to-severe anemia increased from 9 to 14 (25% of cohort).
• Correlation between ELS and hemoglobin measured 7–21 days post-treatment (r = 0.4893) is stronger than at baseline (r = 0.4418), indicating predictive value.

Clinical Implications

Measuring baseline ELS via the non-invasive CO breath test can identify AGC patients at higher risk of developing moderate to severe anemia following anti-tumor therapy. Early identification enables clinicians to implement personalized anemia prevention and management strategies, potentially improving treatment tolerance and patient outcomes. This approach offers a predictive advantage over conventional hemoglobin monitoring alone.

Conclusion

Baseline erythrocyte lifespan is a valuable predictor of anemia development in advanced gastric cancer patients undergoing anti-tumor treatments. Incorporating ELS measurement into clinical practice may enhance anemia risk stratification and guide timely interventions.

References

1. Wei et al. 2023 -- Hemoglobin levels and anemia in gastric cancer prognosis
2. Deng et al. 2023 -- Anemia and gastric cancer progression
3. Levitt et al. 2010 -- CO breath test for erythrocyte lifespan measurement